Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zytiga Pre-chemo Data Impress At ASCO, But Early Trial Termination Could Be An Issue

This article was originally published in The Pink Sheet Daily

Executive Summary

Data from a Phase III trial of Johnson & Johnson’s blockbuster prostate cancer drug Zytiga, which was halted for efficacy in March, were released June 2 at ASCO, but at least one expert in the field questions whether the risk to the eventual clinical results was worth it.

You may also be interested in...



Can Zytiga Prevail In Pre-Chemo Prostate Cancer Without Proof Of Survival Benefit?

J&J’s abiraterone gains FDA clearance for the new claim without statistical significance for its 5-month survival advantage, but Medivation’s Xtandi is waiting in the wings – and its pre-chemo trial, PREVAIL, is likely to show a significant effect.

FDA Approves Zytiga In Earlier Prostate Cancer Setting

FDA approval of Zytiga in the pre-chemo setting gives the androgen blocker a second prostate cancer indication and another revenue stream – but a short remaining patent life and a significant competitive threat may mitigate the achievement.

Data At ASCO From J&J Zytiga Trial’s Early End = Intel For Medivation’s MDV3100 Program

Details from the COU-302 trial of Johnson & Johnson’s Zytiga, stopped early for efficacy in March, were released at the American Society of Clinical Oncology meeting, revealing to Medivation/Astellas insights on how to tweak their ongoing registrational trial for enzalutamide (MDV3100) in the pre-chemo prostate cancer space.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel